. 2021 Sep 21;27(1):192–201. doi: 10.1038/s41380-021-01285-w

Table 1.

Study characteristics of included studies.

Study	Drug	N	Total N males	Dose range (mg)	Ligand	Lag (hours)	Duration (days)	Age (mean ± SD years)	Diagnosis	RoI	Ref. model
Meyer et al. (2004) [17]	Cit	18	NA^a	1–60	DASB	6–13	28	NA^a	Mix of healthy and MDD^b	Str, BT, ACC, PFC, mid, BC	Logan
	Ven	18		2.4–225
	Flu	18		1–60
	Ser	14		10–200
	Par	14		5–60
Klein et al. (2006) [18]	Cit	10	20	10–20	ADAM	6	1	NA^c	Healthy	Mid	SRTM
Klein et al. (2006) [18]	Esc	15		5–20	ADAM	6	1	NA^c	Healthy	Mid	SRTM
Lundberg et al. (2007) [19]	Cit	8	16	20	MADAM	6	1	NA	Healthy	ACC, FC, TC, ins, hip, put, rap	SRTM
Lundberg et al. (2007) [19]	Esc	8	16	10	MADAM	6	1	NA	Healthy	ACC, FC, TC, ins, hip, put, rap	SRTM
Baldinger et al. (2014) [31]	Cit	9	6	20	DASB	6	1 + 25	42.3 ± 7.8	MDD	Accu, ins, amy, cau, put, tha, str, mid	MRTM2
Baldinger et al. (2014) [31]	Esc	10	6	10	DASB	6	1 + 25	42.3 ± 7.8	MDD	Accu, ins, amy, cau, put, tha, str, mid	MRTM2
Klein et al. (2007) [36]	Cit	9	9	20	ADAM	6 + 54	10	28 ± 3	Healthy	Mid	SRTM
Klein et al. (2007) [36]	Esc	6	9	10	ADAM	6 + 54	10	28 ± 3	Healthy	Mid	SRTM
Smith et al. (2011) [38]	Cit	7	4	20–40	DASB	NA	56–70	65 ± 5	MDD	Str, tha	Logan, MRTM2
Houle et al. (2000) [34]	Cit	3	NA	40	DASB	3	1	NA	Healthy	Str, mid, tha	NA
Herold et al. (2006) [37]	Cit	13	11	10	ADAM	6–7	7	NA	MDD	Mid	Logan
Kim et al. (2017) [35]	Esc	12	12	5–30	DASB	3 + 24 + 46	1	23 ± 2.7	Healthy	Put, DRN, cau, tha	MRTM2
Arakawa et al. (2016) [30]	Esc	8	8	10–20	DASB	4 + 24 + 48	1	29.1 ± 4.6	Healthy	Tha	SRTM
	Ser	4		50
	Par	4		20
Catafau et al. (2006) [32]	Par	9	NA^d	20	ADAM	NA	39	NA	MDD	Mid, tha, str	Tissue ratio method
Takano et al. (2006a) [39]	Flv	6	6	50	DASB	5 + 26 + 53	1	24.3 ± 4.8	Healthy	FC, tha, str, hip, amy	MRTM2
Takano et al. (2006b) [40]	Dul	15	15	5–60	DASB	6 + 25 + 49 + 53 + 78	1 + 7	24.1 ± 2.4	Healthy	Tha	MRTM2
Abanades et al. (2011) [28]	Dul	10	10	20	DASB	6, 4	1 + 4	40.2 ± 11	Healthy	Mid, str, tha	SRTM
Areberg et al. (2012) [41]	Vor	35	35	2.5–20	DASB	7	13	NA^a	Healthy	Rap	SRTM
Areberg et al. (2012) [41, 42]	Vor	11	11	2.5–60	MADAM	7	1 + 9	NA^a	Healthy	Rap	SRTM
Frankle et al. (2018) [33]	Des	15	8	25–150	DASB	24^e	3	27 ± 9	Healthy	Mid, tha, amy, str	SRTM

N number of participants, lag (hours) time lag in hours between drug administration and scanning, SD standard deviation, RoI brain region of interest, Ref. model reference model for quantifying binding potential, cit citalopram, ven venlafaxine, flu fluoxetine, ser sertraline, par paroxetine, esc escitalopram, flv fluvoxamine, dul duloxetine, vor vortioxetine, des desvenlafaxine, NA not applicable, MDD major depressive disorder, str striatum, BT bilateral thalamus, ACC anterior cingulate cortex, PFC prefrontal cortex, mid midbrain, BC bilateral cuneus, FC frontal cortex, TC temporal cortex, ins insula, hip hippocampus, put putamen, rap raphe nuclei, accu accumbens, amy amygdala, tha thalamus, cau caudate, DRN dorsal raphe nucleus, SRTM simplified reference tissue model, MRTM-2 multilinear reference tissue model 2.

^aInformation on sex and age provided only for 77 of 82 participants in Meyer 2004 (33 females, 44 males, mean age (SD) 35 (9), and only for both groups combined in Areberg 2012 (46 males, mean age 28 years (21–41).

^bHealthy participants received low doses, unhealthy participants received high doses.

^cMean age data includes four dropouts (26.8 years for all 29 participants).

^dParticipant characteristics include one dropout (6 males, 4 females, mean age (SD) 36 (10.8), range 20–53).

^eUnique to this review